Put Options

6 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $353,529 - $436,977
900 New
900 $421,000
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $274,400 - $328,544
800 New
800 $325,000
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $3.53 Million - $3.94 Million
12,900 Added 330.77%
16,800 $4.86 Million
Q2 2022

Aug 15, 2022

SELL
$234.96 - $292.55 $6.13 Million - $7.64 Million
-26,100 Reduced 87.0%
3,900 $1.1 Million
Q3 2019

Nov 14, 2019

SELL
$166.23 - $187.09 $8.48 Million - $9.54 Million
-51,000 Reduced 62.96%
30,000 $5.08 Million
Q1 2019

May 15, 2019

BUY
$163.73 - $194.7 $13.3 Million - $15.8 Million
81,000 New
81,000 $14.9 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.